Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This study will be conducted in two sequential parts: Part 1 dose escalation and Part 2 dose expansion. In all arms, both mirdametinib and BGB-3245 will be administered orally.
Part 1 is enrolling people with an oncogenic mutation or other genomic aberration of the MPAK pathway who will be assigned to receive different dose levels to test their safety and effectiveness.
Part 2 has three cohorts that will enrol people with different types of cancer.
- Part 2 Cohort A will recruit people with cutaneous melanoma harbouring NRAS mutations.
- Part 2 Cohort B will recruit people with non-small cell lung cancer harbouring KRAS mutations.
- Part 2 Cohort C will recruit people with non-small cell lung cancer or cutaneous melanoma harbouring BRAF Class II or Class III mutation or BRAF Fusion mutation.
Conditions
This trial is treating people with advanced solid cancers
Eligibility
Exclusion
- Central Nervous System metastases, leptomeningeal carcinomatosis or untreated spinal cord compression
- History of glaucoma
- Active parathyroid disorder or history of malignancy associated hypercalcemia
- Clinically significant cardiac disease within the past 6 months of signing ICF
- History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of treatment from these agents
- Severe or uncontrolled systemic disease
- Inability to swallow oral medications
- Clinically significant active infection (HIV, Hepatitis B or Hepatitis C)
- History of or ongoing Immune Thrombocytopenia (ITP), Von Willebrand disease and/or other past or present bleeding disorders
- Underlying medical conditions in investigator's opinion to be unfavorable to be a part of the study
- Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose or anticipates need for major surgery while on study
- Systemic anti-cancer therapy within 2 weeks or 5 half-lives before first dose
- Concomitant systemic or glucocorticoid therapy within 2 weeks before first dose
- Concomitant medicines that are strong CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives before first dose
- Live vaccine within 4 weeks before first dose
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You are able to swallow medication by mouth.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
SpringWorks Therapeutics, Inc
Scientific Title
A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information